Across TCGA pan-cancer cohorts, ENTPD6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ENTPD6 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ENTPD6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ENTPD6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where ENTPD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.993	0.525	.004	6	view →
PDAC	OS	Median	All	0.410	0.935	.038	3	view →
LSCC	DFS	Median	All	0.865	0.669	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ENTPD6 tumor-vs-normal RNA expression · all ENTPD6 data types